The Brainclinics Foundation


Brainclinics was founded in 2001 as an independent research institute by dr. Martijn Arns and specializes in advancing our understanding of the brain. The results of our research are a valuable aid in the treatment and prevention of symptoms such as mood-, concentration-, impulse control-, and sleep problems, often seen in disorders such as depression, ADHD, and insomnia. Over the last 20 years, Brainclinics has pioneered the application of neurofeedback in the treatment of ADHD and insomnia, was one of the first to recognize the importance of the circadian clock and sleep problems underlying many symptoms like impaired concentration and impulse control, specifically in ADHD, while also pioneering and refining magnetic brain stimulation (rTMS) in the treatment of depression and obsessive–compulsive disorder (OCD). In 2019 the legal structure was changed, and the non-profit Brainclinics Foundation was established. The Brainclinics Foundation’s primary mission is best summarized as: Applied Neuroscience from the clinic, to the clinic. Therefore, the two pillars of the foundation are formed by Research Institute Brainclinics and Brainclinics Insights (the publishing division).


At Research Institute Brainclinics researchers have published over 170 scientific publications on these and related topics and continue to collaborate with researchers and universities around the world ranging from Australia, Germany, Belgium, the United States to Colombia. A key topic of our research revolves around ‘personalized medicine’, going beyond the traditional ‘diagnostic-thinking’ and focusing on individual differences that can help optimize and individualize treatment and prevent symptoms from occurring. Our research has resulted in 4 patents and several spin-offs, such as Brainquiry, where the first ever wireless Bluetooth based EEG amplifier was developed in 2003 and the first wrist-worn heart-rate device in 2005 (nine years before Apple launched the Apple Watch with similar technology). Other spin-offs are Brainclinics Education, where specialistic applied neuroscience training courses were developed focused on rTMS, neurofeedback and QEEG, and Brainclinics Treatment, where our unequalled knowledge and expertise on personalized neuromodulation treatments are applied to benefit people worldwide. In 2015, Brainclinics Education and Brainclinics Treatment were acquired by the neuroCare Group, where courses are still taught by neuroCademy, and neuromodulation treatments that followed from Brainclinics Research are offered in >15 neuroCare clinics worldwide.


Brainclinics Insights is the publishing division of our foundation. Its mission is to make the knowledge, expertise and especially ‘Insights’ gained through our research, widely available through books, PhD theses and interactive media.

To serve the goal of the Brainclinics Foundation, all proceeds are fully invested into Research Institute Brainclinics and Brainclinics Insights, which creates an unprecedented synergy between these divisions and makes it possible to perform research and share new future insights as well.

At the Brainclinics Foundation, it is all about the research and its application!

Had a great symposium on EEG neurofeedback @rtFIN2019 together with @neuromeditate @s_geppert Glad to have some EEG work in between all the fMRI and fNIRS neurofeedback work!

Just published: Annual variation in attentional response after methylphenidate treatment, and iSPOT-A study
Congrats @vollebregt_m and also thx. to @circadian247

Had a great Brainclinics Foundation research day yesterday, with Sebastian Olbrich, Hartmut Heinrich and full-team. Looking forward to great new insights to come, from the clinic, to the clinic!

Could #biomarkers help predict acute #suicide risk? This #EEG study investigated whether #MDD patients with suicidal attempts or ideation have unique spatial-frequency power characteristics versus MDD patients without suicidal ideation or behavior. http://bit.ly/2QO0tHx

Just published: Stability of frontal alpha asymmetry (FAA) in depressed patients: an @iSPOT_Studies
FAA robust trait marker resistant to state and drug effects, illustrates clinical utility in predicting SSRI response.
Congrats @NikitaVinne

Load More...